This Viewpoint discusses the challenges of tracking participants and outcomes after clinical trials end and how more accurately reported National Clinical Trial codes would generate substantial value for researchers, patients, and policymakers.
Haye et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: